☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
P-II
HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China
March 7, 2025
Cytoki Pharma Reports the First Patient Dosing with CK-0045 in the P-II Trial for Treating Obesity and Type 2 Diabetes
November 4, 2024
Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT
October 30, 2024
The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase
October 30, 2024
EyePoint Pharmaceuticals Reports Data From Ongoing P-II (VERONA) Study of Duravyu in Diabetic Macular Edema (DME)
October 29, 2024
Shuttle Pharma Reports the Completion of Clinical Trial Site Enrollment for the P-II Study of Ropidoxuridine for Glioblastoma
October 29, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.